Multiple Myeloma

>

Latest News

Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma
Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

March 14th 2025

Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies
Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

March 9th 2025

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.
Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

March 7th 2025

Updated findings from the MAIA trial support the use of frontline daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.
Daratumumab Regimen Shows Continued Efficacy in Transplant-Ineligible NDMM

March 6th 2025

A real-world study assessed treatment patterns and outcomes of elderly patients with lenalidomide-refractory multiple myeloma after 1 to 3 therapy lines.
Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments

March 4th 2025

Video Series
Video Interviews
Podcasts
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

More News